SCHEMBL25366120

SCHEMBL25366120

Cc1cc(Cl)nc(NC2CC2)c1N

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 1/20 0.36
PDE10A Q9Y233 1/20 0.36
CHRM3 P20309 3/20 0.35
PDE4A P27815 3/20 0.35
PDE4B Q07343 3/20 0.35
PDE4C Q08493 3/20 0.35
PDE4D Q08499 3/20 0.35
CHRM4 P08173 4/20 0.35
CYP3A4 P08684 4/20 0.35
CYP2D6 P10635 3/20 0.35
CYP1A2 P05177 2/20 0.35
TSHR P16473 2/20 0.35
CLK4 Q9HAZ1 2/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPK1 P28482 1/20 0.35
IRAK4 Q9NWZ3 2/20 0.34
OPRK1 P41145 1/20 0.34
NUDT1 P36639 2/20 0.33
CYP2C9 P11712 2/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26111515 0.94 PDE10A (0.40) PIK3CAPDE10ACHRM3PDE4APDE4B
SCHEMBL26102950 0.86 PIK3CA (0.34) PIK3CACHRM4
SCHEMBL30611996 0.77 CYP3A4 (0.36) CYP3A4CYP1A2TSHRALDH1A1KMT2A
SCHEMBL16244697 0.77 CYP3A4 (0.36) CYP3A4CYP1A2TSHRALDH1A1KMT2A
SCHEMBL14768722 0.75 KMT2A (0.44) PDE10ACHRM3PDE4APDE4BPDE4C
SCHEMBL30943973 0.75 CYP3A4 (0.35) CYP3A4CYP1A2TSHRALDH1A1KMT2A
SCHEMBL12936033 0.74 NUDT1 (0.55) CHRM3PDE4APDE4BPDE4CPDE4D
SCHEMBL25366543 0.74 KMT2A (0.48) CHRM3PDE4APDE4BPDE4CPDE4D
SCHEMBL14768686 0.73 CCR4 (0.49) ALDH1A1LMNA
SCHEMBL20337764 0.70 ACP1 (0.38) CHRM3PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250177363-A1 SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 BRISTOL-MYERS SQUIBB COMPANY (US) 2025-06-05 US disclosed
EP-4479135-A1 SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 Bristol-Myers Squibb Company (US) 2024-12-25 EP disclosed
CN-118786130-A Substituted imidazopyridinyl compounds useful as TLR9 inhibitors 百时美施贵宝公司 2024-10-15 CN disclosed
WO-2023159154-A9 SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 BRISTOL-MYERS SQUIBB COMPANY (US) 2024-10-10 WO disclosed
WO-2023159154-A1 SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 BRISTOL-MYERS SQUIBB COMPANY (US) 2023-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250177363-A1 SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 TLR9, TLR3, TLR1 PIK3CA 940/4885PDE10A 2415/4885CHRM3 887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.